[Federal Register Volume 68, Number 226 (Monday, November 24, 2003)]
[Notices]
[Pages 65965-65966]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-29245]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 030-34730]


Notice of Finding of No Significant Impact and Availability of 
Environmental Assessment for License Amendment of Materials License No. 
07-00455-40, Bristol-Myers Squibb Pharma Company, Wilmington, DE

ACTION: Notice of availability of Environmental Assessment and Finding 
of No Significant Impact.

-----------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT: Sattar Lodhi, Nuclear Materials Safety 
Branch 2, Division of Nuclear Materials Safety, Region I, 475 Allendale 
Road, King of Prussia, Pennsylvania, 19406; telephone (610) 337-5364; 
fax (610) 337-5269; or by e-mail: [email protected].

SUPPLEMENTARY INFORMATION:

I. Introduction

    The U.S. Nuclear Regulatory Commission (NRC) is considering the 
issuance of a license amendment to Bristol-Myers Squibb Pharma Company 
for Materials License No. 07-00455-40, to authorize release of its 
facilities in Wilmington, Delaware for unrestricted use and has 
prepared an Environmental Assessment (EA) in support of this action in 
accordance with the requirements of 10 CFR part 51. Based on the EA, 
the NRC has concluded that a Finding of No Significant Impact (FONSI) 
is appropriate.

II. EA Summary

    The purpose of the proposed action is to allow for the release of 
the licensee's Wilmington, Delaware, facilities for unrestricted use. 
The subject license was originally issued to DuPont Pharmaceuticals 
Company on February 25, 1999, to use licensed material at the site. 
Bristol-Myers Squibb Pharma Company acquired the license on October 9, 
2001, and continued the use of radioactive materials for research and

[[Page 65966]]

development, and preparation and distribution of radioactive drugs at 
the site. On April 29, 2003, Bristol-Myers Squibb Pharma Company 
requested that NRC release the facility for unrestricted use. Bristol-
Myers Squibb Pharma Company has conducted surveys of the facility and 
determined that the facility meets the license termination criteria in 
subpart E of 10 CFR part 20.

III. Finding of No Significant Impact

    The NRC staff has evaluated Bristol-Myers Squibb Pharma Company's 
request and the results of the surveys and has concluded that the 
completed action complies with 10 CFR part 20. The staff has prepared 
the EA (summarized above) in support of the proposed license amendment 
to terminate the license and release the facility for unrestricted use. 
On the basis of the EA, the NRC has concluded that the environmental 
impacts from the proposed action are expected to be insignificant and 
has determined not to prepare an environmental impact statement for the 
proposed action.

IV. Further Information

    The EA and the documents related to this proposed action, including 
the application for the license amendment and supporting documentation, 
are available for inspection at NRC's Public Electronic Reading Room at 
http://www.nrc.gov/reading-rm/adams.html (ADAMS Accession Nos. 
ML033170352, ML031330024, ML031360368, ML031400814, ML031400824, 
ML031400830, ML031400836, ML031400847, ML031400886, and ML031400887). 
These documents are also available for inspection and copying for a fee 
at the Region I Office, 475 Allendale Road, King of Prussia, 
Pennsylvania, 19406.

    Dated at King of Prussia, Pennsylvania, this 14th day of 
November, 2003.

    For the Nuclear Regulatory Commission.
John R. McGrath,
Acting Chief, Nuclear Materials Safety Branch 2, Division of Nuclear 
Materials Safety, Region I.
[FR Doc. 03-29245 Filed 11-21-03; 8:45 am]
BILLING CODE 7590-01-P